This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Recent Price Trend in Syndax (SNDX) is Your Friend, Here's Why
by Zacks Equity Research
Syndax (SNDX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Does Syndax (SNDX) Have the Potential to Rally 67% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 66.9% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Syndax (SNDX) Climb 48% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 47.7% upside potential for Syndax (SNDX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Incyte (INCY) Collaborates With Syndax for Chronic GVHD Candidate
by Zacks Equity Research
Incyte (INCY) collaborates with Syndax to develop and commercialize axatilimab for chronic graft-versus-host disease and other fibrotic diseases.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 40.54% and -24.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Syndax Pharmaceuticals (SNDX) Q2 Earnings Expected to Decline
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?
by Zacks Equity Research
Syndax (SNDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF
by Zacks Equity Research
The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.
Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD
by Zacks Equity Research
The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.
Implied Volatility Surging for Syndax Pharmaceuticals (SNDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Syndax Pharmaceuticals (SNDX) stock based on the movements in the options market lately.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of -9.80% and -0.26%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Syndax Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Syndax Pharmaceuticals.
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 4.35% and 0.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Plug Power (PLUG) to Report Q4 Earnings: What to Expect?
by Zacks Equity Research
Plug Power's (PLUG) Q4 results are expected to reflect gains from healthy demand in material handling, on-road and stationary markets. High costs and international exposure might have been dragging.
Syndax Pharmaceuticals, Inc. (SNDX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Syndax Pharmaceuticals, Inc. (SNDX).
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 14.58% and -0.26%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Syndax Pharmaceuticals (SNDX) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Syndax (SNDX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Syndax (SNDX) stock based on the movements in the options market lately.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of -6.82% and -2.82%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Syndax Pharmaceuticals (SNDX) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 5.36% and -0.26%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Syndax (SNDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Syndax (SNDX) delivered earnings and revenue surprises of 10.53% and -0.26%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?